{"nctId":"NCT03867201","briefTitle":"Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients","startDateStruct":{"date":"2019-08-26","type":"ACTUAL"},"conditions":["Migraine"],"count":557,"armGroups":[{"label":"Erenumab","type":"EXPERIMENTAL","interventionNames":["Biological: Erenumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Erenumab","otherNames":["AMG334"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"key inclusion Criteria:\n\n1. History of at least 5 attacks of migraine\n2. ≥ 15 headache days of which ≥ 8 headache days meet criteria as migraine days during the baseline period\n3. \\>=80% diary compliance during the baseline period\n\nKey exclusion Criteria:\n\n1. Older than 50 years of age at migraine onset\n2. History of cluster or hemiplegic headache\n3. Evidence of seizure or major psychiatric disorder\n4. Cardiac or active hepatic disease\n5. Pregnant or nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period","description":"A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for ≥4 continuous hours, and meeting at least one of the following criteria:\n\n1. ≥2 of the following pain features:\n\n   * Unilateral\n   * Throbbing\n   * Moderate to severe\n   * Exacerbated with exercise/physical activity\n2. ≥1 of the following associated symptoms:\n\n   * Nausea and/or vomiting\n   * Photophobia and phonophobia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.19","spread":"0.46"},{"groupId":"OG001","value":"-6.62","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Migraine-related Disability and Productivity as Measured by the mMIDAS During the Last 4 Weeks of the 12-week Treatment Period","description":"The modified MIDAS is a 5-item self-administered questionnaire that sums the number of productive days lost over the past month in two settings: the workplace and the home. The MIDAS also assesses disability in family, social, and leisure activities. The MIDAS score is the sum of missed days due to a headache from paid work, housework, and non-work (family, social, leisure) activities; and days at paid work or housework where productivity was reduced by at least half.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.67","spread":"1.20"},{"groupId":"OG001","value":"-12.93","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With at Least 50% Reduction From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period","description":"A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for ≥4 continuous hours, and meeting at least one of the following criteria:\n\n1. ≥2 of the following pain features:\n\n   * Unilateral\n   * Throbbing\n   * Moderate to severe\n   * Exacerbated with exercise/physical activity\n2. ≥1 of the following associated symptoms:\n\n   * Nausea and/or vomiting\n   * Photophobia and phonophobia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Monthly Acute Headache Medication Days During the Last 4 Weeks of the 12-week Treatment Period","description":"An acute headache medication day was defined as a day when medication was taken to treat acute headache.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.34","spread":"0.39"},{"groupId":"OG001","value":"-4.66","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events as a Measure of Safety","description":"Number of subjects with adverse events was assessed separately in the double-blind treatment period (DBTP) and the open-label treatment period (OLTP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-AMG 334 Antibodies","description":"anti-AMG 334 antibodies assessed for binding and neutralizing)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":279},"commonTop":["Upper respiratory tract infection","COVID-19","Constipation","Dizziness","Nasopharyngitis"]}}}